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g.2013.0Abstract Background and purpose: Prader-Willi Syndrome (PWS) is a complex multisystemic dis-
order characterized by hyperphagia, severe obesity and muscular hypotonia. So, it is essential to
seek an ideal program to help in solving such a widespread problem. The purpose of this study
was to investigate the effect of conservative therapy (diet and exercises) versus intra-gastric balloon
in PWS patients. Ten children born with PWS from both sexes ranging in age from 8 to 15 years
were assigned into two groups of equal number. Study group I received conservative therapy in
the form of diet regimen (a low caloric diet) and aerobic exercises on a stationary bicycle while study
group II underwent intra-gastric balloon. Evaluation procedures in the form of initial evaluation
and measurement of Body mass index (BMI) and lipid proﬁle parameters were conducted for each
child of the two groups before and after 6 months of treatment. The results revealed no signiﬁcant
difference when comparing the pre-treatment mean values of the two study groups (I and II), while
signiﬁcant improvement was observed in all the measuring variables of the two groups when com-
paring their pre- and post-treatment mean values. Signiﬁcant difference was also observed when
comparing the post-treatment results of the two groups in favor of the study group I. It concluded
that conservative therapy could be the ﬁrst choice of treatment of PWS morbid obesity, while
BioEnterics Intra-gastric balloon (BIB) came in the second choice.
 2013 Ain Shams University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Prader-Willi Syndrome (PWS) is a genetically determined dis-
order that affects approximately one in 14,000 people of both3596123.
m (N.S. Thabet).
Shams University.
g by Elsevier
y. Production and hosting by Elsev
1.003genders. The genetic basis is the absent expression of the pater-
nally active genes in the PWS critical region on chromosome
15 [1]. It is characterized by muscular hypotonia, ligament lax-
ity, hyperphagia, severe obesity, short stature, hypogonadism,
and dysmorphic features. Both hypotonia and excessive body
weight may affect the development of motor and functional
skills of PWS individuals. A central feature of the syndrome
is an excessive appetite, with overeating behavior apparent as
early as 2 years of age. In addition, people with PWS usually
require special help at school, due to the presence of mild
learning disabilities, as well as having a short stature and other
phenotypic characteristics [2]. A proposed pathophysiologicalier B.V. All rights reserved.
260 H.N. Ashem et al.explanation for the overeating behavior is hypothalamic dys-
function with failure of the feedback mechanism which would
normally lead to feelings of fullness and loss of feelings of hun-
ger after eating [3].
The most widely accepted deﬁnition of obesity relates to the
body mass index (BMI): weight (kg)/height (m2). Children
above the 85th percentile are classiﬁed overweight and those
above the 95th percentile, obese [4].
Caloric restriction has remained as the ministry of treat-
ment of obesity. It improves most of the lipid abnormalities.
One of the best ways to achieve healthier weight is to adopt
a healthful diet with an energy intake that does not exceed
expenditure, is low in fat, and provides adequate amounts of
all food groups, including whole grains and cereals, fruits
and vegetables [5].
Physical activity is recognized as an integral part of obesity
treatment with other therapeutic means, Exercise is an activity
requiring physical exertion done for the sake of health. Exer-
cises use a variety of muscle groups continuously and rhythmi-
cally, increasing heart rate and breathing. Speciﬁc aerobic
activities include walking, jogging, bicycling, swimming, tennis
and cross-country skiing [6].
Surgical treatment of obesity is based on two techniques
gastric – restricting technique (gastric band, stapling, and bal-
loon) and gastric restricting and malabsorptive technique
(Gastric bypass) [7].
BioEnterics Intra-gastric balloon (BIB). It is a liquid-ﬁlled,
intragastric balloon model that decreases preprandial hunger,
increases postprandial satiety, and promotes weight loss in
the short term [8]. Additionally, the intra-gastric balloon is
thought to help individuals to modify their eating habits by
providing a self-education tool [9].
A clinical trial was conducted on PWS patients to compare
between the effects of conservative therapy in the form of diet
regimen (a low caloric diet) plus aerobic exercises on a stationary
bicycle and intra-gastric balloon in reducing patients’ weight.2. Patients and methods and procedures
2.1. Patients
Ten PWS patients from both sexes were eligible for participa-
tion according to the following criteria: their ages ranged from
8 to 15 years, they had a body mass index more than 35. All
patients were conscious and ambulant. Five PWS patients
had the same surgical technique done by the same surgeon
for the intra-gastric balloon group. Children were subse-
quently excluded for any of the following reasons: they had
BMI < 30, esophagitis > grade 1, and hiatal hernia >5 cm
and medically unstable as determined by history or medical re-
cords, as cardiac patients.
Patients were classiﬁed into two equal groups; study group
I, ﬁve patients received conservative therapy in the form of diet
regimen (a low caloric diet) a well-balanced diet of 1.200 kcal/
day and aerobic exercises on a stationary bicycle, while study
group II, ﬁve patients underwent bioenterics intra-gastric
balloon.
Evaluation procedures in the form of initial evaluation and
measurement of BMI and lipid proﬁle parameters were con-ducted for each child of the two groups before and after
6 months of treatment.
2.2. Methods
All procedures were explained to the parents and participants;
the experimental protocol was explained in detail for caregiv-
ers of the children before the initial assessment. Each of them
signed a consent form prior to participation.
2.2.1. Initial evaluation procedures
A diagnosis of PWS was made according to the Holm and
Cassidy criteria and conﬁrmed by genetic analysis using meth-
ylation test and/or ﬂuorescence in situ hybridization (FISH)
for chromosome 15 [10].
Each child was examined medically in order to exclude any
abnormal medical problem.
2.2.2. Estimation of lipid proﬁle
After fasting for at least 12 h, 3 ml of venous blood was ex-
tracted from the dorsal hand vein and allowed to clot at
37 C in the water bath, then serum was separated using a cen-
trifuge for the estimation of serum triglycerides and cholesterol
level [11].
2.2.3. Measurement of body mass index
Weight and height scale: A valid and reliable weight and height
scale was used. Then the body mass index was calculated:
[Body mass index = body weight (kg)/height (m2)]. It is plot-
ted on percentile charts [12].
2.3. Treatment procedures
The procedures of this protocol were achieved under the fol-
lowing steps:
2.3.1. For study group I
Conservative therapy group (dieting and aerobic exercises).
2.3.1.1. Recommended diet regimen. Children received a low
calorie diet. The caloric intake was below 1200 cal/day. This
diet was used for 3 days at a time and followed by 4 days nor-
mal eating and then repeated for 6 months [13].
Day 1:
Breakfast: skimmed milk with tea, ½ grapefruit, 1 slice
toast and 1 cup peanut butter.
Lunch: ½ cup tuna or 1 slice cheese, 1 slice toast.
Dinner: 2 slices of any type meat, 1 cup string beans and 1
small apple.
Day 2:
Breakfast: skimmed milk with tea, 1 egg, slice toast and ½
banana.
Lunch: 1 cup cottage cheese or ½ cup tuna, 5 saltine
crackers.
Dinner: 1 cup broccoli or cabbage, ½ cup carrots, ½ bana-
nas and 1 cup vanilla ice cream.
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Breakfast: 5 saltine crackers, 1 slice cheddar cheese and 1
small apple.
Lunch: 1 boiled egg, 1 slice toast.
Dinner: 1 cup tuna, 1 cup carrot, 1 cup grains, 2 cup canta-
loupe and ½ cup vanilla ice cream.
2.3.1.2. Program of aerobic training. Exercises were performed
on the electronic bicycle ergometer as the following stages:
First stage (warming up):
Consisted of 5 min warming up in the form of pedaling at
the speed of 60 revolutions per min without load.
Second stage (active stage):
Duration: 30 min.
Mode: pedaling at speed of 60 revolutions per min.
Load: adjusted load to achieve 60% of the predictive age
maximal heart rate which was calculated by the following
equation [14]:Table 1 Study group I mean values of BMI before and after
treatment in kg/m2.
Variables Study group I
Range Mean ± SDMaximal heart rate ¼ 220 age ðyearsÞ
Moderate work load ¼ 60% of maximal heart rate:
The heart rate will be measured through a pulsometer at-
tached to patient’s ear.
Third stage (cooling down):
Consisted of 5 min cooling down in the form of pedaling at
the speed of 60 revolutions per min without load [6].
Duration and frequency: 3 sessions per week for 6 months [6].
2.3.2. For study group II
2.3.2.1. Intra-gastric balloon group. Bioenterics intra-gastric
balloon is an endoscopic device for temporary treatment of
morbid obesity. It consists of a silicon smooth elastic balloon
with self sealing radiopaque valve designed to remain in the
gastric cavity for a period of 6 months. Its use is totally revers-
ible and repeatable [15].
 Bioenterics intra-gastric balloons were implanted during the
study period. Placement was performed with patients under
sedation or general anesthesia, immediately after upper gas-
trointestinal endoscopy if this revealed no contraindication
(e.g., potentially bleeding lesion, large hiatal hernia).
 The balloon was inﬂated with 500–650 ml of saline mixed
with 10 ml of methylene blue. Patients were instructed:
 To expect nausea, vomiting, and abdominal cramps dur-
ing the following 72 h.
 To take a liquid diet for 72 h, including protein-rich d-
rinks (e.g., Clinutren; Nestle´, Vevey, Switzerland) and,
starting at day 4, to progressively follow a personalized
balanced-deﬁcit diet of 1000 kcal per day less than their
usual intake, with approximately 15% of energy derived
from proteins, 30% or less from fats, and the remainder
from carbohydrates [16].Before 43.5–52.6 48.96 ± 3.387
After 27.2–31.8 29.48 ± 1.77
Wilcox signed Ranks test 2.023
Asymp. sig. 0.043
Signiﬁcant S
Percentage (%) of improvement 39.78%3. Data analysis
The raw data were analyzed using the SPSS program to deter-
mine the mean ± standard deviation for each measuringvariables of the two groups before and after 6 months of treat-
ment. Tests included in this study were independent t-test and
paired t-test.
4. Results
The collected data from this study represent the statistical
analysis of the Body mass index and lipid proﬁle parameters,
which were measured before and after 6 months of treatment
for the two groups. The raw data of the measured variables
for the two groups were statistically treated to determine the
mean and standard deviation. The Mann–Whitney test and
the Wilcox signed Ranks test were then applied to examine
the signiﬁcance of the treatment conducted for each group.
The obtained results in this study revealed no signiﬁcant
differences when comparing the pre-treatment mean values
of the two groups. Signiﬁcant improvement was observed in
all measuring variables of the two study groups (I and II),
when comparing their pre and post-treatment mean values.
After treatment signiﬁcant differences were also observed
when comparing the post-treatment results of the two groups
in favor of the study group I.
As revealed from Table 1 and Fig. 1, signiﬁcant reduction
was observed in the mean values of Body mass index for the
study group I at the end of treatment as compared with the
corresponding mean values before treatment.
Also, Table 2 and Fig. 2, showed a signiﬁcant reduction in
the mean values of Body mass index for the study group II at
the end of treatment as compared with the corresponding
mean values before treatment.
No signiﬁcant difference was observed when comparing the
pre-treatment mean values of Body mass index of the two
groups. While signiﬁcant improvement was observed when
comparing the post-treatment mean values of Body mass index
of the two groups in favor of the study group I (P< 0.05) as
shown in Fig. 3.
As revealed from Table 3 and Fig. 4, signiﬁcant reduction
was observed in the mean values of lipid proﬁle parameters
for the study group I at the end of treatment as compared with
the corresponding mean values before treatment.
Also, Table 4 and Fig. 5, showed a signiﬁcant reduction in
the mean values of lipid proﬁle parameters for the study group
II at the end of treatment as compared with the corresponding
mean values before treatment.
No signiﬁcant difference was observed when comparing the
pre-treatment mean values of lipid proﬁle parameters of the
two groups signiﬁcant improvement was also observed when
comparing the post-treatment mean values of lipid proﬁle
Figure 1 Pre and post values of BMI of study group I.
Table 2 Study group II mean values of BMI before and after
treatment in kg/m2.
Variables Study group II
Range Mean ± SD
Before 43.5–52.6 48.94 ± 3.42
After 35.3–43.3 40.34 ± 3.14
Wilcox signed Ranks test 2.023
Asymp. sig. .043
Signiﬁcant S
Percentage (%) of improvement 17.6%
Figure 2 Pre and post values of BMI of study group II.
Figure 3 Pre and post values of BMI of both groups of the
study.
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(P< 0.05) as shown in Fig. 6.
5. Discussion
Obesity associated with Prader-Willi Syndrome is likely to be
progressive. Weight gain between the ages of 1 and 6 years,
leads most PWS patients to develop morbid obesity, affecting
the development of motor and functional skills. PWS patients
are characterized by an increase in BMI which is demonstrated
to be associated with an increase in functional impairment with
further reductions in physical activity. Body weight reduction
is mandatory to reduce the risk of cardio-respiratory and met-
abolic complication and to improve life expectancy.
In our study the pre-treatment mean values of BMI of our
patients showed a signiﬁcant increase in their values which
indicated that those children had a signiﬁcant feature of obes-ity, This comes in agreement with Capodaglio et al. [17] who
demonstrated that, PWS patients presented with reduced lean
body mass and increased fat to lean mass ratio not only when
compared with lean patients but also in relation to obese
patients. Menegoni et al. [18] also reported that obesity associ-
ated with PWS is often massive and many individuals exceed
by more than 200% their ideal body weight. In addition to
obesity and muscular hypotonia, PWS shows dysmorphic fea-
tures that can affect the development of motor and functional
skills.
The post-treatment results of the present study indicated
that both groups induced signiﬁcant reduction in BMI, serum
cholesterol and triglycerides which was higher in the conserva-
tive therapy group than the intra-gastric balloon group. Group
I who received a selected diet program, with aerobic exercise
training, showed the highest signiﬁcant reduction in BMI, ser-
um cholesterol and triglycerides. This result reinforced the
effectiveness of conservative therapy on improving metabolic
activity. The same result was also reported by Scheimann et
al. [19], as increase in the lipolytic responses to isoprenaline
and dobutamine occur during the use of a hypocaloric diet
[13]. Very low calorie diet also results in rapid loss, often
3–4 lb or more per week, and rapid medical improvement, such
as signiﬁcant reduction in blood pressure, decrease in serum
cholesterol of 20–25% and dramatic lowering of glucose level
in diabetics [5]. However, the more the restrictive diet, the
more is the rapid weight loss, but the greater the risk of non
compliance [20].
Aerobic high intensity exercise on obese women led to a de-
crease in body weight and body mass index after 2 months be-
cause exercise training is a major modiﬁable component of
total daily energy expenditure [21]. But the signiﬁcant effect
was after 6 months of intervention [22]. Also exercise prevents
weight gain and promotes weight loss [23]. An increase in exer-
cise energy expenditure, without a compensatory increase in
food intake, is also an effective means for achieving weight loss
[24]. Low amounts of exercise at moderate or high intensity are
associated with potentially beneﬁcial changes in plasma lipid
proﬁle. However, higher levels of high intensity exercise re-
sulted in more pronounced changes in lipoprotein and were re-
quired to increase the high density lipoprotein cholesterol level,
without signiﬁcant weight loss [25].
This improvement was also conﬁrmed by Tall [26] who re-
ported that the improvement in lipid proﬁle variables and insu-
lin sensitivity that are associated with habitual exercise is also
seen after a single session of exercise. This ﬁnding could
Table 3 Study group I mean values of lipid proﬁle parameters before and after treatment.
Variables Study group I
Total cholesterol Triglycerides
Range Mean ± SD Range Mean ± SD
Before 231–253 241.8 ± 8.075 145–180 162.8 ± 14.44
After 179–201 192.2 ± 10.75 80–122 103.20 ± 19.22
Wilcox signed Ranks test 2.023 2.023
Asymp. sig. 0.043 0.042
Signiﬁcant S S
Percentage (%) of improvement 20.5% 36.6%
Figure 4 Pre and post values of lipid proﬁle parameters of study
group I.
Figure 5 Pre and post values of lipid proﬁle parameters of study
group II.
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ing in muscle are a fundamental mechanism underlying many
of the observed changes in the lipid proﬁle.
Exercise is associated with an increase in lipoprotein lipase
activity in adipose tissue and muscles, which lowers LDL and
chylomicron triglyceride levels and enhances the clearance of
cholesterol-rich LDL and chylomicron remnant. LDL, and tri-
glycerides are exchanged for cholesterol ester in LDL, and
HDL, a process mediated by cholesteryl ester transfer protein,
and the triglycerides in HDL, and LDL are then hydrolyzed by
lipases, causing a decrease in the size of the particles. Exercise
and weight loss also reduce the level of cholesteryl ester trans-
fer protein perhaps because a fraction of this protein is made in
adipose tissue [27].
Cycle ergometer leads to an increase in the energy expendi-
ture. The total daily energy expenditure can be divided intoTable 4 Study group II mean values of lipid proﬁle parameters bef
Variables Study group II
Total cholesterol
Range M
Before 231–255 2
After 209–230 2
Wilcox signed Ranks test
2.023
Asymp. sig.
0.042
Signiﬁcant
S
Percentage (%) of improvement
9.4%several components: resting metabolic rate, which accounts
for approximately 60–70% of 24 h energy expenditure; the en-
ergy cost of feeding approximately 10% of 24 h energy expen-
diture; and the thermal effect of physical activity or exercise,
which is the most variable component and may vary from
15% of 24 h energy expenditure in sedentary people to even
400% in professional cyclists under extreme circumstances
[28]. The body mass index and abdominal fat were decreased
by training on a cycle ergometer for 3 days/week for 6 weeks
because there was a decrease in total amount of stored calories.
This decrease in energy stores is obviously the results of a neg-
ative energy balance so that exercise produces a decrease in en-
ergy intake leading to a reduction in weight [29]. Cycling is an
effective form of exercise for improvements in the cardiovascu-
lar function [30].ore and after treatment.
Triglycerides
ean ± SD Range Mean ± SD
41.2 ± 9.497 148–180 163.4 ± 15.043
18.6 ± 7.60 120–140 129.40 ± 7.335
2.023
0.042
S
20.8%
Figure 6 Pre and post values of lipid proﬁle parameters of both groups of the study.
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tric balloon and showed a signiﬁcant reduction in BMI and
serum cholesterol and triglycerides.
The post-treatment results of the study group II was in
agreement with Dhruva and Redberg [31] who suggested that
70% of intra-gastric balloon were successful in treatment of
obesity and excellent in terms of weight loss maintaining or
good weight loss results. Also 60% of patients were off medi-
cations for related diseases as hyperlipidemia after the removal
of bioenterics intra-gastric balloon [32].
In another study on 30 patients with BMI 42.4, and hyper-
lipidemia, eight patients treated by BIB, four patients showed
normal levels, two lowered levels and two unchanged values
post operatively [33]. The early treatment may produce better
results and minimize complication [34]. There was also
improvement of some morbid conditions associated with obes-
ity (hypertension, diabetes, hyperlipidemia), and reduction of
mortality [35]. The estimate of BIB effectiveness at balloon re-
moval came from 15 studies that summarized data from up to
3,608 patients. These estimates were 14.7 kg loss. Two studies
provided data on maintenance of weight lost 1 year after treat-
ment [36]. The inﬂated balloon occupies a portion of the gas-
tric volume and theoretically reduced the capacity for food.
This method is far less invasive than gastric surgery for reduc-
ing stomach capacity [37].
In conclusion, both conservative therapy and intra-gastric
balloon are effective in treatment of PWS morbid obesity with
high recommendation for using conservative therapy.
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